Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Operating Leases: 2018-2024

Historic Operating Leases for Cytokinetics (CYTK) over the last 7 years, with Dec 2024 value amounting to $112.6 million.

  • Cytokinetics' Operating Leases fell 3.57% to $110.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.7 million, marking a year-over-year decrease of 3.57%. This contributed to the annual value of $112.6 million for FY2024, which is 6.51% down from last year.
  • Latest data reveals that Cytokinetics reported Operating Leases of $112.6 million as of FY2024, which was down 6.51% from $120.4 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Operating Leases peaked at $126.9 million during FY2022, and registered a low of $440,000 during FY2020.
  • In the last 3 years, Cytokinetics' Operating Leases had a median value of $120.4 million in 2023 and averaged $120.0 million.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 79.95% in 2020, then skyrocketed by 25,406.59% in 2021.
  • Yearly analysis of 5 years shows Cytokinetics' Operating Leases stood at $440,000 in 2020, then spiked by 25,406.59% to $112.2 million in 2021, then grew by 13.07% to $126.9 million in 2022, then decreased by 5.10% to $120.4 million in 2023, then dropped by 6.51% to $112.6 million in 2024.